CD158k/KIR3DL2 is a useful marker for identifying neoplastic T‐cells in Sézary syndrome by flow cytometry

Bahler, David W.; Hartung, L; Hill, Sally M.; Bowen, Glen M.; Vonderheid, Eric C.

doi:10.1002/cyto.b.20395

Cited by 67 publications

(54 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In normal individuals, expression of CD158k is highly restricted to a minor NK cell subset and rare CD3+ CD8+ circulating T lymphocytes [37]. On the other hand, in patients with SS, CD158k is highly expressed on circulating Sé zary cells [36,38,39]. Gene expression analysis has revealed that T-plastin (a member of a highly conserved cytoplasmic protein family), EphA4, the Ephreceptor subfamily of transmembrane protein-tyrosine kinases, and the transcription factor Twist, which functions as a regulator of mesodermal differentiation, are all aberrantly expressed on Sé zary cells [40,41].…”

Section: Sé Zary Cellsmentioning

confidence: 98%

Erythrodermic cutaneous T-cell lymphoma: How to differentiate this rare disease from atopic dermatitis

Miyagaki

Sugaya

2011

Journal of Dermatological Science

View full text Add to dashboard Cite

Section: Sé Zary Cellsmentioning

confidence: 98%

Erythrodermic cutaneous T-cell lymphoma: How to differentiate this rare disease from atopic dermatitis

Miyagaki

Sugaya

2011

Journal of Dermatological Science

View full text Add to dashboard Cite

“…Loss of CD26 expression is also useful in the identification of Sezary cells, being observed in 50% of cases [135][136][137]. More recently, the aberrant expression of the MHC class I-binding, killer immunoglobulin-like receptor (KIR) CD158j, normally expressed by natural killer cells, was described in the majority of patients examined with SS [138,139]. Molecular studies, including detection of a clonal TCR gene rearrangement by PCR and the presence of a clonal cytogenetic abnormality, provide evidence of T-cell clonality.…”

mentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

“…CD158k is expressed by tumor T cells of Sezary syndrome, advanced MF, and pc-ALCL. [171819202122] CD158k acts as an inhibitory coreceptor in Sezary cells given its ability to downmodulate CD3-dependent early signaling events. In addition, our data provide evidence for a possible role of KIR3DL2 in the maintenance of a high circulating malignant-cell burden by preventing activation-induced cell death.…”

Section: Iph4102 (Anti-cd158k Monoclonal Antibody)mentioning

confidence: 99%

New targeted treatments for cutaneous T-cell Lymphomas

Bagot

2017

Indian J Dermatol

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCLs) represent a group of rare and heterogeneous diseases that are very difficult to treat at advanced stages. The development of monoclonal antibodies is a new hope for the treatment of these diseases. Alemtuzumab (Campath) is a humanized IgG1 kappa monoclonal antibody specific for CD52, an antigen expressed by most T and B lymphocytes. Alemtuzumab may frequently induce long-term remissions in patients with Sezary syndrome but high-dose treatments lead to severe cytopenia, immune depletion, and opportunistic infections. This treatment is less efficient in mycosis fungoides (MF). Brentuximab vedotin is a chimeric anti-CD30 monoclonal antibody conjugated to monomethyl auristatin E, a cytotoxic antitubulin agent. Brentuximab vedotin is a very interesting new treatment for advanced tumor MF, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferative disorders. The main limiting adverse event is neurosensitive peripheral neuropathy. Mogamulizumab is a humanized anti-C-C chemokine receptor Type 4 monoclonal antibody with a defucosylated Fc region leading to increased antibody-dependent cellular cytotoxicity. Mogamulizumab is very efficient on aggressive peripheral T-cell lymphomas, particularly adult T-cell leukemia/lymphoma and CTCLs, especially on the blood component of tumor cells. The main limiting events are related to the concomitant depletion of regulatory T-cells. IPH4102 is a humanized monoclonal antibody that targets the immune receptor KIR3DL2/CD158k. Preclinical results with this antibody offer proofs of concept for the clinical development of IPH4102 to treat patients with advanced CTCL.

show abstract

CD158k/KIR3DL2 is a useful marker for identifying neoplastic T‐cells in Sézary syndrome by flow cytometry

Abstract: Enumeration of neoplastic T-cells in peripheral blood specimens is necessary for the diagnosis of

Cited by 67 publications

References 25 publications

Erythrodermic cutaneous T-cell lymphoma: How to differentiate this rare disease from atopic dermatitis

Erythrodermic cutaneous T-cell lymphoma: How to differentiate this rare disease from atopic dermatitis

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

New targeted treatments for cutaneous T-cell Lymphomas

Contact Info

Product

Resources

About